Koninklijke Philips N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 feb 2009 - 16:04
Statutaire naam
Koninklijke Philips N.V.
Titel
Philips and Immunetrics join forces to research advanced solutions for infectious disease in critical care
Bericht
February 3, 2009
PHILIPS AND IMMUNETRICS JOIN FORCES TO RESEARCH ADVANCED SOLUTIONS FOR INFECTIOUS DISEASE IN CRITICAL CARE
Nashville, Tenn., USA — Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Immunetrics Inc. today announced they have entered into a joint development agreement to explore future-generation approaches to the problem of infectious disease in critical care. This announcement was made at the annual Congress of the Society of Critical Care Medicine, taking place January 31 – February 4 in Nashville, Tenn. Philips currently owns a 29% stake in Immunetrics, a biosimulation company based in Pittsburgh, Pennsylvania, USA.
The partnership unites Philips’ strength in patient monitoring and the design and implementation of applications to help clinicians make more informed care decisions, and Immunetrics’ strengths in the dynamic modeling and simulation of complex biological systems. Under the joint development agreement, Philips Research and Immunetrics will study the combination of advanced bioinformatics and computer modeling to identify opportunities to reduce the incidence and improve the management of systemic infection, a major complicating factor among many critically ill patients.
Critical care is a branch of medicine that involves the specialized treatment of patients with acute, life-threatening illness or injury. It is an area of persistent unmet need and significant consumption of healthcare resources. For example, critical care expense in the USA represents the equivalent of nearly one percent of its gross domestic product.
Sepsis, a life-threatening, systemic inflammatory response to infection, is an example of a key medical challenge for which Philips Research and Immunetrics seek to develop new mechanisms for early and effective intervention. In the USA and Europe sepsis afflicts more than two million people each year and incidence of the condition is growing. Despite the best currently available treatment, approximately one in
Datum laatste update: 25 december 2025